No Data
The A-share sector of innovative drugs is gaining strength, with betta pharmaceuticals rising over 10%.
On November 20, according to Gelonghui, Betta Pharmaceuticals and Yifang Bio rose over 10%, while China Securities Co., Ltd., Nossar, Tigermed, Innocare, Haisco Pharmaceutical Group and others rose more than 7%. On the news front, the statistics from the research department of Xinyin (Hong Kong) Capital indicate that the number of innovative drug INDs and NDAs has returned to growth after the low point in 2022. In Q3 of this year, there were 1,033 drug clinical approvals, a year-on-year increase of 25%, with a total of 8 first-class innovative drugs approved for market release, doubling year-on-year. Xinyin (Hong Kong) Capital's research department believes that domestic innovative drugs are accelerating into a "new quality development stage."
InventisBio Gets Regulatory Approval to Market Gesorexel Tablets
Yifang Biotechnology (688382.SH): Type 1 innovative drug Gexolezepam tablet approved for market launch.
Yifang Biological (688382.SH) issued an announcement that the company and Zhengda Tianqing Pharmaceutical Group Co., Ltd. (referred to as "...
Yifang Biological-U (688382): Steadily advancing clinical progress, D-1553 approved for imminent listing.
Event: The company released the third quarter report of 2024, achieving revenue of 0.019 billion yuan in the first three quarters, a year-on-year decrease of 84.94%; net profit attributable to the parent company was -0.305 billion yuan; non-net profit attributable to the parent company was -0.313 billion yuan;经
bocom intl: sino biopharm's 3Q24 performance exceeded expectations, acquiring the controlling rights of the first A-share company.
Bocom Intl released a research report stating that Sino Biopharm (01177) had a 14.3% year-on-year increase in revenue to 5.47 billion yuan, with adjusted net income increasing by 58.0% to 0.6 billion yuan, both exceeding the bank's expectations. Management maintains a double-digit revenue growth guidance for the full year. In addition, the company acquired control of Haobobo (688656.SH) entering the immunodiagnostics track with an acquisition price of 33.74 yuan/share. After completion, Haobobo will become the first subsidiary of Sino Biopharm listed on the A-share market, with the bank believing its product portfolio will complement the company's respiratory, autoimmune, and other disease areas.
Yifang Biotech Report for the Third Quarter of 2024
No Data
No Data